ZimVie/$ZIMV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ZimVie
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
Ticker
$ZIMV
Sector
Primary listing
Employees
1,770
Headquarters
Website
ZimVie Metrics
BasicAdvanced
$532M
-
-$0.70
2.08
-
Price and volume
Market cap
$532M
Beta
2.08
52-week high
$19.01
52-week low
$8.15
Average daily volume
548K
Financial strength
Current ratio
2.374
Quick ratio
1.411
Long term debt to equity
55.924
Total debt to equity
56.817
Interest coverage (TTM)
0.38%
Profitability
EBITDA (TTM)
40.964
Gross margin (TTM)
65.31%
Net profit margin (TTM)
-4.39%
Operating margin (TTM)
1.42%
Effective tax rate (TTM)
-122.79%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
0.51%
Return on equity (TTM)
-4.76%
Valuation
Price to revenue (TTM)
1.181
Price to book
1.29
Price to tangible book (TTM)
8.85
Price to free cash flow (TTM)
92.976
Free cash flow yield (TTM)
1.08%
Free cash flow per share (TTM)
0.203
Growth
Revenue change (TTM)
-2.20%
Earnings per share change (TTM)
-94.63%
3-year revenue growth (CAGR)
-23.00%
3-year earnings per share growth (CAGR)
-47.35%
What the Analysts think about ZimVie
Majority rating from 2 analysts.
Bulls say / Bears say
Archimed’s all-cash $19.00 per share offer values ZimVie at about $730 million, a 99% premium over the 90-day volume-weighted average price, signaling strong investor value recognition (GlobeNewswire).
ZimVie posted a 15.0% adjusted EBITDA margin in Q2 2025, 150 basis points higher year-over-year, highlighting improved operating efficiency in its dental business (TipRanks).
The exclusive distribution agreement with Osstem Implant Co. gives ZimVie access to China’s premium dental implant market, which exceeds 10 million units annually, positioning it for significant international expansion (GlobeNewswire).
ZimVie withdrew its full-year 2025 outlook after the pending Archimed acquisition, making it harder to predict future results and reducing investor visibility (GuruFocus).
Net sales in Q2 2025 were essentially flat at $116.7 million, edging down 0.1% year-over-year, showing limited revenue growth in a competitive environment (TipRanks).
UBS lowered its price target on ZimVie to $10 from $16 while keeping a neutral rating, pointing to declining revenue and muted implant volume growth as near-term challenges (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
ZimVie News
AllArticlesVideos
ZIMVIE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ZimVie Inc. - ZIMV
Business Wire2 months ago
ZIMV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ZimVie Inc. Is Fair to Shareholders
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ZimVie stock?
ZimVie (ZIMV) has a market cap of $532M as of September 14, 2025.
What is the P/E ratio for ZimVie stock?
The price to earnings (P/E) ratio for ZimVie (ZIMV) stock is 0 as of September 14, 2025.
Does ZimVie stock pay dividends?
No, ZimVie (ZIMV) stock does not pay dividends to its shareholders as of September 14, 2025.
When is the next ZimVie dividend payment date?
ZimVie (ZIMV) stock does not pay dividends to its shareholders.
What is the beta indicator for ZimVie?
ZimVie (ZIMV) has a beta rating of 2.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.